Clinical trials: Decompensated Liver Cirrhosis
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Decompensated Cirrhosis
A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.
This will be a randomized double blind study which will be conducted on patients admitted to Department of Hepatology from June 2013 to may 2014 at ILBS, New Delhi.
- Trial name
- NCT01902511
- Testing
- G-CSF+Erythropoetin, G-CSF
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis, Portal Vein Thrombosis
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It can extend downstream to the portal branches, or upstream to the splenic and/or the mesenteric veins.
- Conditions
- Decompensated Cirrhosis, Portal Vein Thrombosis, Bleeding Varices
- Trial name
- NCT01326949
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), ET+NSBB
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Air Force Military Medical University, China
Decompensated Cirrhosis
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
The purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) transplantation in patients with Decompensated Cirrhosis.
- Trial name
- NCT02786017
- Testing
- Conventional therapy, Injectable Collagen Scaffold + HUC-MSCs
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Sciences
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Decompensated Cirrhosis
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural…
- Trial name
- NC-CHRM (NCT07131280)
- Testing
- Gcsf, Darbepoetin, Standard Medical Treatment
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated…
- Trial name
- LiverGut (NCT06533852)
- Testing
- Fecal Microbiome Transplantation (FMT)
- Where
- 8 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Liver Cirrhosis
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects…
- Trial name
- NCT01904409
- Testing
- Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet
- Where
- 120 sites in United States, Russia
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Antibiotic Toxicity, Liver Cirrhosis
A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
The investigators designed an observational multicenter explorative in vivo study to investigate the changes in ceftriaxone pharmacokinetics in blood and ascites.
- Conditions
- Antibiotic Toxicity, Liver Cirrhosis, Renal Insufficiency, Ceftriaxone Overdose
- Trial name
- TACTILE (NCT05960006)
- Testing
- No intervention (observational study)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Acute Kidney Injury, Hepatorenal Syndrome
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with…
- Trial name
- NCT02049125
- Where
- 4 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- University of Sao Paulo
Decompensated Cirrhosis and Ascites
Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
The goal of this clinical trial is to compare the nutritional parameters after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL.
- Trial name
- NCT06121479
- Testing
- Branched-chain amino acid
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Decompensated Cirrhosis, Bacterial Infections
Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)
Study to comparing conventrional antibiotic strategies versus regimens guided by epidemiological surveillance in infected patients with cirrhosis.
- Trial name
- SURVIC (NCT05783661)
- Testing
- Conventional antibiotic strategies, Regimens guided by epidemiological surveillance
- Where
- Spain
- Volunteers
- 198 people
- Sponsor
- Eva Bonfill
Ascites, Decompensated Cirrhosis
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients…
- Trial name
- NCT04112199
- Testing
- BIV201 continuous infusion
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- BioVie Inc.
Stem Cell Transplantation, Cirrhosis
Autologous Bone Marrow Stem Cells in Cirrhosis Patients
Liver cirrhosis (LC) is the end stage of chronic liver disease. The liver transplantation is one of the only effective therapies available to such patients.
- Trial name
- NCT00713934
- Testing
- CD133, BM-MNC
- Where
- 2 sites in Iran
- Volunteers
- 7 people
- Sponsor
- Royan Institute
Liver Cirrhosis
Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
The project is about evaluation of albumin and midodrine versus albumin alone in outcome of refractory ascites in patients with decompensated cirrhosis. Cirrhosis is a leading cause of disability and mortality worldwide.
- Trial name
- NCT04816240
- Testing
- Midodrine, Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Malnutrition
Establishment of a Model for Predicting the Prognosis of HBV-related Decompensated Liver Cirrhosis Based on RFH-NPT
For all countries, chronic liver disease and liver cirrhosis is one of the important disease burdens. Malnutrition is an important complication of liver cirrhosis, which always runs through the course of liver cirrhosis.
- Trial name
- NCT05513651
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Decompensated Cirrhosis
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
Three sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg).
- Trial name
- HCL001 (NCT07488546)
- Testing
- Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Huicun Medical Technology Co., Ltd.
Hepatic Encephalopathy, Decompensated Cirrhosis
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Rationale Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
- Conditions
- Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
- Trial name
- HERB (NCT06538077)
- Testing
- Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose
- Where
- India
- Volunteers
- 336 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh